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bound with high efﬁciency almost all terminally sialylated glycans represented on the array regardless of the
type of glycosidic linkage. In contrast, substitution of G141E alone, or in combinations with the other two
amino acid substitutions, signiﬁcantly restricted virus glycan-binding capabilities. All virus variants
possessing this substitution lost the ability to bind glycans with α2-6 glycosidic linkage as well as most of
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Inﬂuenza B virus circulates almost exclusively in the human
population, indicating a long evolutionary adaptation and balance
between the virus and the host (Chen and Holmes, 2008; Lamb and
Krug, 2001). Transfer of the inﬂuenza B virus to an unnatural host, such
as embryonated chicken eggs (eggs) used for vaccine manufacture,
requires some adjustments of viral components to the new environ-
ment (Burnet andBull, 1943;Oxford et al., 1990; Robertson et al., 1985,
1993; Robertson, 1993; Saito et al., 2004; Williams and Robertson,
1993). Since cell surface glycans are used as the primary receptor for
virus attachment and internalization (reviewed in Matrosovich et al.,
2006), a key impediment for the efﬁcient replication of inﬂuenza B
viruses in eggs is the spectra of cell surface glycans encountered in that
substrate. Thus, human inﬂuenza viruses have the afﬁnity to the
sialylated carbohydrates with α2-6 glycosidic linkage between
terminal sialic acid and the galactose (Baum and Paulson, 1990; Blixt. Lugovtsev).
Inc.et al., 1993; Connor et al., 1994; Couceiro et al., 1993; Gambaryan et al.,
1995, 1997; Rogers and Paulson, 1983; Rogers and D'Souza, 1989),
whereas cells of chorioallantoic membrane of chicken embryonated
egg predominantly contain sialylated carbohydrates with α2-3
glycosidic linkage (Ito et al., 1997; Sriwilaijaroen et al., 2008). In
previous studies, we found that adaptation of human inﬂuenza B virus
strain B/Victoria/504/2000 to efﬁcient replication in eggs was a result
of subtle changes in the vicinity of the receptor-binding domain of the
viral hemagglutinin (HA), with no mutations in any other gene
segments (Lugovtsev et al., 2005, 2007). Here, we report how the
previously identiﬁed amino acid (AA) substitutions, namely G141E,
R162M, and D196Y, individually or in combinations, affect the
receptor-binding characteristics of the virus. Eight virus constructs,
generated by reverse genetics and previously characterized for growth
characteristics (Lugovtsev et al., 2007), were analyzed for their glycan-
binding proﬁles using glycanmicroarray technology (Blixt et al., 2004;
Stevens et al., 2006a,b; www.functionalglycomics.org). Three distinct
patterns of virus bindingwere revealed, representing (i) a low-growth
egg-derived reference virus, (ii) viruses with substitution G141E, and
(iii) viruses with R162M and/or D196Y (without G141E).
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Binding proﬁles of each virus variant are shown on Fig. 1 and
binding to individual glycan structures is represented in Table 1. Table 1
includes all sialylated glycans from the printed glycan array version
2.1. Glycans with N-acetylneuraminic acid moieties are segregated
into twomajor groups based on the type of glycosidic linkage (α2-3 or
α2-6) as well as in accordance with the structure of the inner core of
the carbohydrate. Glycoproteins and glycans with other types of sialic
acid were grouped separately at the end of the table. Virus variant 1,
representing the parental reference virus B/Victoria/504/2000 with
limited growth capabilities in eggs, demonstrated a clear preference
for glycans with terminal sialic acid (N-acetylneuraminic acid,
Neu5Ac) linked to the subterminal galactose (Gal) through α2-6
glycosidic linkage. At the same time, not all of 11 sialylated glycans
with α2-6 linkage presented on the array (v2.1) were bound by virus
with similar efﬁciency. The shortest structures sufﬁcient for detect-
able virus binding (though very weak) were simple disaccharides,
containing only sialic acid and galactose (Neu5Acα2-6Galβ-sp; glycan
73). However, the strongest ﬂuorescent signal on the array, which
reﬂects high binding energy and high afﬁnity, was observed with the
glycan structures where Neu5Ac is linked throughα2-6 linkage to the
Type-II motif (LacNAc; Neu5Acα2-6Galβ1-4GlcNAcβ−; glycans 13–
14, 66–70). Composition of the third sugar from the non-reducing end
of sialylated glycans also inﬂuenced the binding: replacement of the
GlcNAc by the non-acetylated glucose (Glc) signiﬁcantly reduced
binding afﬁnity (glycans 71–72). Sulfation of the sialylated Type-II
motif at the sixth carbon (6-O-SO3) of the third sugar (−GlcNAc−)
had no affect on binding strength (Neu5Aca2-6Galβ1-4(6OSO3)
GlcNAcβ-sp; glycan 66). Elongation of the primary glycan chain
(sialylated Type-II motif: Neu5Acα2-6Galβ1-4GlcNAcβ1−) by addi-
tional link of Type-II motif (−3Galβ1-4GlcNAcβ1−; glycan 70), or
when the terminally sialylated Type-II motif is attached to the bi-
antennary high-mannose core (glycans 13–14), contributed to more
efﬁcient binding. Presence of the fucose residue at the second and
third Type-II links of the long carbohydrate chain (glycan 69) had no
effect on binding. Noteworthy, the strong virus binding was also
observedwhen the Neu5Acwas linked viaα2-6 glycosidic linkage to a
relatively rare glycan type, LacdiNAc: Neu5Acα2-6GalNAcβ1-
4GlcNAcβ-sp (glycan 65).
At the same time, virus variant 1 showed poor capability to bind
structures terminally sialylated through α2-3 glycosidic linkage
(Neu5Acα2-3Galβ−). Only linear glycans, with sialic acid attached
to single or reiterated Type-II (LacNAc) (−Galβ1-4GlcNAcβ−) or
Type-I (Lewisc) (−Galβ1-3GlcNAcβ−) motifs were bound by the
virus with the strength sufﬁcient to generate a distinguishable signal
(glycans 41, 46–48, 51–55, 57–60, 89). Elongation of the primary
carbohydrate chain (sialylated Type-II motif: Neu5Acα2-3Galβ1-
4GlcNAcβ1−) by addition of two or three reiterated motifs (Type-I
or Type-II) did not improve binding (glycans 46, 57, 60, 89). Sulfation
of the N-acetylglucosamine at the sixth carbon (−6-O-SO3) of either
motif (Type-I and Type-II) decreased binding efﬁciency (glycans 38,
49). Fucosylation of Type-I motif (Lewisa; Neu5Acα2-3Galβ1-3
(Fucα1-4)GlcNAcβ−; glycan 39) also precluded binding, whereas
fucosylation of Type-II motif (Lewisx; Neu5Acα2-3Galβ1-4(Fucα1-3)
GlcNAcβ−; glycans 51–55) had no detectable effect. Apart from
sialylation through α2-6 linkage, terminal sialylation of LacdiNAc
through α2-3 linkage (glycan 37) resulted in a very weak virus
binding. Binding to the sialylated Type-III motif (Core 1) (Neu5Acα2-
3Galβ1-3GalNAcα-sp; glycans 24, 42) as well as with short disacchar-
ide Neu5Acα2-3Galβ-sp (glycan 44) or with ganglioside-like struc-
tures (Neu5Acα2-3Galβ1-4Glcβ-sp, GM3; glycans 61–62) was also
very weak. No binding was detected with disaccharide Neu5Acα2-
3GalNAcα-sp (glycan 36). Modiﬁcation of the sialylated subterminal
galactose by attachment of sulfate (to the sixth carbon, 6-O-SO3) or
any other constituent (such as N-acetylgalactosamine to the forthcarbon, second sialic acid, etc.) completely abrogated virus binding
(glycans 10, 15–20, 23, 30–33, 35, 63).
Amino acid substitutions R162M and D196Y, singly or combined
(virus variant 5, variant 4, and variant 10, respectively), had
signiﬁcant but somewhat similar effects on the receptor-binding
properties of the viral HA. They enabled the mutant viruses to bind
with high efﬁciency a broader spectrum of sialylated glycans with
both types of glycosidic linkage (α2-3 and α2-6). These virus variants
efﬁciently bound all linear glycans with α2-6 glycosidic linkage
presented on the array.
The spectrum of the sialylated glycans with α2-3 glycosidic
linkage which was bound by these three mutant viruses included
most of the linear forms of major types of theN-linked glycans (Type-I
motif (Lewisc): Neu5Acα2-3Galβ1-3GlcNAcβ−, glycans 47–48; Type-
II motif: Neu5Acα2-3Galβ1-4GlcNAcβ−); glycans 51–55, 57–60, 89;
and O-linked glycans (Type-III motif: Neu5Acα2-3Galβ1-3GalNAcα-
sp; glycans 24, 42), ganglioside type (Neu5Acα2-3Galβ1-4Glcβ-sp;
glycans 61–62). The LacdiNAc (Neu5Acα2-3GalNAcβ1-4GlcNAcβ-sp;
glycan 37) was bound only by virus variant 5 (with single R162M
substitution). Amino acid substitutions R162M and/or D196Y enabled
the mutant viruses to bind short disaccharide structures, such as the
sialylated galactose (Neu5Acα2-3/6Galβ-sp; glycans 44, 73). At the
same time, none of these viruses were able to bind Neu5Acα2-
3GalNAcα-sp (glycan 36) or a Globo-series structure (represented on
the array by a single variant NeuAcα2-3Galβ1-3GalNAcβ1-3Galα1-
4Galβ1-4Glcβ-sp; glycan 45). Likewise, none of the viruses bound any
structures if other moieties were attached to the sialylated terminal
galactose or if sialic acid was not terminating a non-reducing end of
glycans structure (glycans 10, 15–20, 23, 30–33, 35, 63).
In spite of the fact that both R162M and D196Y mutations resulted
in viruses with expanded binding capabilities, some speciﬁc differ-
ences in binding proﬁles were found in relation to each of these two
amino acid substitutions. These differences in binding proﬁles were
associated with variations in the inner part of the glycan chain
terminally sialylated with α2-3 linkage. Thus, only virus variant 5
with the single amino acid substitution R162M was able to bind the
sialylated Type-I motif with sulfate group at the sixth carbon of the
GlcNAc (6-O-SO3) (Su-Lewisc: Neu5Acα2-3Galβ1-3(6OSO3)GlcNAc-
sp; glycan 38) or the Type-I motif if its GlcNAc is fucosylated at the
fourth carbon (Lewisa: Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ-sp;
glycan 39) as well as LacdiNAc with α2-3 linkage (glycan 37) and
ganglioside (glycan 34). At the same time, presence of tyrosine (Y) at
position 196 of the HA (D196Y) completely abrogated the effect of
R162M (virus variant 10). In contrast, only viruses with D196Y
substitution in their HA (variant 4 and variant 10) were able to bind
efﬁciently the sialylated Type-II motif containing sulfate substituent at
the sixth carbon (6-O-SO3) of the GlcNAc (Neu5Acα2-3Galβ1-4
(6OSO3)GlcNAcβ-sp; glycan 49). Another noticeable difference
between the R162M and D196Y substitutions is their different effect
on the binding of longer oligosaccharide chains. All mutant viruses
bind long oligosaccharides with high efﬁciency provided that the
sialylated non-reducing end is represented by Type-II motif (glycans
60, 89, 51, 55, 57). In this case, the type of the followingmotifs (Type-I
or Type-II) in the oligosaccharide chain is not critical (e.g., glycans 60
and 89). However, if the non-reducing end of the long oligosaccharide
is represented by sialylated Type-I motif and if the subsequent link is
represented by either Type-I or Type-II motif (glycan 46, 88), such
structures were bound only by viruses with R162M (virus variants 5
and 7). Tyrosine at position 196 of viral HA (virus variants 4, 6, and 10)
precluded binding of the viruses to those glycan structures.
Comparison of the binding patterns of the viruses with individual
mutations (variants 4 and 5) with that of the virus variant with both
mutations (variant 10) suggests that the effect of D196Y substitution
is stronger than that of R162M, and in most cases it abrogated the
effect of the latter. Thus, in all cases when the effects on virus binding
of individual amino acid substitutions differed, the effect of R162M
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virus variant 4 (with single D196Y substitution) and variant 10 (with
two substitutions R162M and D196Y) had almost identical binding
proﬁles.
In contrast to the effect of the two amino acid substitutions
described above (R162M and D196Y), the G141E substitution had a
remarkably different effect on the receptor-binding properties of
the viral HA. Either alone (virus variant 3) or even in the presence
of R162M and/or D196Y (viruses variants 2, 6, and 7), the G141E
substitution dramatically narrowed the spectrum of glycans that
could be bound by the mutant viruses. Characteristic to all four virus
variants with G141E amino acid change was an almost complete loss
of the ability to bind glycan structures with α2-6 glycosidic linkage,
selectively limiting the binding preferences to several glycan types
terminally sialylated via α2-3 glycosidic linkage. All four viruses
bound most efﬁciently with the long linear oligosaccharide chains
consisting of two or three links of Type-I and/or Type-II motifs
(penta- and heptasaccharides), provided that the non-reducing
terminally sialylated motif in the chain is represented exclusively by
Type-II motif (e.g., Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-(3/4)
GlcNAcβ−; glycans 57, 60, 89). Virus variant 2 and variant 6 also
efﬁciently bound O-linked Type-III motif (Neu5Acα2-3Galβ1-3Gal-
NAcα-sp; glycans 24, 42). Introduction of the additional substitution
R162M (virus variant 7) did not alter the binding properties resulted
from the substitution G141E (virus variant 3), whereas combination
of substitutions G141E and D196Y (variant 6) led to the binding
proﬁle similar to that of virus variant 2, which contains all three
substitutions (G141E, R162M, and D196Y). Thus, substitution
R162M had an effect on the receptor-binding properties only on
the background of the original amino acid sequence (compare virus
variant 1 and variant 5), whereas its inﬂuence was almost
completely abrogated if either of the additional substitutions
(R162M and D196Y) were present. In addition, viruses containing
both G141E and D196Y amino acid substitutions (variant 2 and
varant-6) did not bind pentasaccharide glycans with Type-I
sialylated non-reducing end but contributed to the better binding
of O-linked glycans (mucin-type).
Six glycoproteins (AGP, AGP-A, AGP-β1; ceruloplasmin, ﬁbrino-
gen, and transferrin) were used in the v2.1 version of the glycan array
as complex compounds carrying variety of different glycans on their
surface (1–6 on the array). Although it is hard to standardize such
compounds in terms of amount and type of glycoproteins, the binding
patterns of the viruses showed clear regularities. No binding was
observed with ﬁbrinogen, indicating that it has no carbohydrate
structures that could be recognized by any of the tested viruses. Other
ﬁve glycoproteins were bound in a similar pattern by all viruses which
have no G141E substitution. In contrast, viruses with G141E
substitution were unable to bind the glycoproteins (with the
exception to virus variant 2, which showed very weak binding),
indicating the presence of types of carbohydrates, which could serve
as ligands for virus variants 1, 4, 5, and 10, and the absence (or rare
representation) of the types of carbohydrates, which could be
recognized by G141E containing viruses.
None of the eight analyzed viruses bound the glycan structures
with terminal Neu5Ac linked to Gal through β conﬁguration
(Neu5Acβ2-6Gal−; glycans 76–78), or with terminal Neu5Ac linked
to another sialic acid (Neu5Acα2-8Neu5Acα2−; glycans 25–29, 74–
75), or when the non-reducing end of the glycans was terminated by
another type of sialic acid: N-glycolylneuraminic acid (Neu5Gcα2-3/Fig. 1. Binding proﬁles of virus variants of B/Victoria/504/2000 with amino acid substitu
containing N-acetylneuraminic acid (Neu5Ac) with α2-3 glycosidic linkage; green bars repr
the glycans sialylated via α2-8 glycosidic linkage; red bars on the left side of the graphs repre
than Neu5Ac (see Table 1 and Table S1 for details). Samples of each virus variant were prepa
ﬂuorophore. Labeled samples were equilibrated to 5000–10,000 HAU/ml (using 0.5% chicken
glycans printed in replicate (n=6); the relative ﬂuorescence units (RFU) values are an ave6Gal−; glycans 79–86), KDN (KDNα2-3Galβ−; glycans 21–22), or 9-
O-acetylneuraminic acid (9-O-AcNeu5NAcα2-6Gal−; glycans 11–
12). No binding was observed with individual sialic acid (not linked
to another sugar moiety; glycans 7–9) or non-sialylated glycans
(almost 200 glycans on the array version v2.1; data not shown). None
of the viruses were able to bind the glycans if besides sialic acid
moiety (with either type of glycosidic linkage) an additional sugar or
substituent was attached to the same (subterminal) galactose residue
(glycans 10, 15–20, 23, 30–33, 35, 63). No binding was observed with
sialylated Globo-series structure (glycan 45).
Discussion
Although many isolates of inﬂuenza B viruses are able to replicate
in eggs, the level of virus accumulation is often below practical
requirements of vaccine manufacturing. Serial passage in eggs
remains the sole strategy to select high-growth virus variants.
However, it almost inevitably leads to amino acid substitutions in
viral hemagglutinin, associated with the adjustment of the receptor-
binding capabilities (Burnet and Bull, 1943; Gambaryan et al., 1997,
1999; Matrosovich et al., 2006; Oxford et al., 1990; Robertson et al.,
1985, 1990, 1993, Robertson, 1993; Saito et al., 2004; Williams and
Robertson, 1993). The egg-derived B/Victoria/504/2000, used in our
study as a reference virus, already had one amino acid change N196D
in HA if compared to the original human isolate (GenBank accession
nos. ABQ10176 and AAT69425, after 2 and 12 egg passages,
respectively). Although this substitution, leading to elimination of a
glycosylation site, is a characteristic for most of the egg-derived
inﬂuenza B viruses, it does not contribute to high-growth capabilities
in chicken eggs. In our previous studies, we found that additional
passaging in eggs led to a selection of high-growth virus variants
with two (R162M and D196Y) or three (G141E, R162M, and D196Y)
amino acid substitutions in the vicinity of the receptor-binding
domain of HA (Lugovtsev et al., 2005). Using reverse genetics
technology, we created a set of virus variants containing each of the
found amino acid substitutions alone or in combinations (on the
background of the already pre-existing egg-derived substitution
N196D) and investigated the effect of each substitution on viral
growth phenotype (Lugovtsev et al., 2007). In the study described
here, we analyzed the effect of each amino acid substitution on the
viral receptor-binding properties. The whole-virion virus prepara-
tions labeled with the ﬂuorescent dye were used to mimic the virus
binding under natural conditions. The printed glycan microarray
platform, designed by Consortium of Functional Glycomics (www.
functionalglycomics.org), provided a wide spectrum of glycans that
presumably could be bound by inﬂuenza viruses and proved to be a
valuable tool for characterization of inﬂuenza A viruses (Belser et al.,
2008; Blixt et al., 2004; Kumari et al., 2007; Stevens et al., 2006a,b,c,
2008). This is the ﬁrst report of application of this technology for
inﬂuenza B viruses. Our data are consistent with that from previous
reports (Baum and Paulson, 1990; Gambaryan and Matrosovich,
1992, Gambaryan et al., 1995, 1997, 1999; Govorkova et al., 1999;
Matrosovich et al., 1993, 1997, 2006; Suzuki et al., 1987, 1992;
Suzuki, 1994, 2005; Xu et al., 1994, 1996) and at the same time
signiﬁcantly expand our knowledge about receptor speciﬁcities of
inﬂuenza B viruses.
Among a wide variety of the glycans represented on the array, only
glycans terminally sialylated by N-acetylneuraminic acid (Neu5Ac)
were recognized by the viruses. The non-sialylated structures ortions G141E, R162M, and D196Y in hemagglutinin. Yellow bars represent the glycans
esent the glycans containing Neu5Ac with α2-6 glycosidic linkage; blue bars represent
sent the glycoproteins. All other glycans on the array (black bars) have sialic acid other
red by sucrose density gradient puriﬁcation followed by direct labeling with Alexa-488
RBCs) and applied for glycan array at room temperature for 1 h. The array comprised of
rage of four values after removal of the highest and lowest of the six replicates.
Table 1
Binding of B/Victoria/504/2000 virus variants with amino acid substitutions in hemagglutinin to glycans (array version v2.1).
No. on
the graph
Glycans composition Virus 1 Virus 4 Virus 5 Virus 10 Virus 2 Virus 3 Virus 6 Virus 7
Refer. D196Y R162M R162M
D196Y
G141E
R162M
D196Y
G141E G141E
D196Y
G141E
R162M
α2-6 73 Neu5Acα2-6Galβ-Sp8 +a +++ ++++ +++ − − − −
64 Neu5Acα2-6GalNAcα-Sp8 ++ +++ ++++ ++ − − − −
71
72
Neu5Acα2-6Galβ1-4Glcb-Sp0/Sp8 + ++++ ++++ ++++ − − − −
67
68
Neu5Acα2-6Galβ1-4GlcNAcβ-Sp0/Sp8 +++ ++++ ++++ ++++ − − ± −
66 Neu5Acα2-6Galβ1-4[6OSO3]GlcNAcβ-Sp8 +++ ++++ ++++ ++++ − − ± −
70 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ-Sp0
++++ ++++ ++++ ++++ − − ± −
69 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-
4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0
++++ ++++ ++++ ++++ − − − −
13
14
Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3
(Neu5Acα2-6Galb1-4GlcNAcβ1-2Manα1-6)
Manβ1-4GlcNAcβ1-4GlcNAcβ-Spp
++++ ++++ ++++ ++++ − − ± −
65 Neu5Acα2-6GalNAcβ1-4GlcNAcβ-Sp0 ++++ ++++ ++++ ++++ − − ± −
19 Galβ1-3(Neu5Acα2-6)GlcNAcβ1-4Galβ1-4Glcβ-Sp10 − − − − − − − −
17
63
Galβ1-3(Neu5Acα2-6)GalNAcα-Sp8
Galβ1-3(Neu5Acβ2-6)GalNAcα-Sp8
Neu5Acα2-6(Galβ1-3)GalNAcα-Sp8
− − − − − − − −
35 Neu5Acα2-3(Neu5Acα2-6)GalNAcα-Sp8 − − − − − − − −
43 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-Sp8 − ++++ ++ ++++ + − + −
α2-3 44 Neu5Acα2-3Galβ-Sp8 ± ++++ ++++ +++ − − − −
61
62
Neu5Acα2-3Galb1-4Glcβ-Sp0/Sp8 ± ++++ ++++ +++ − − − −
36 Neu5Acα2-3GalNAcα-Sp8 − − − − − − − −
58
59
Neu5Acα2-3Galβ1-4GlcNAcβ-Sp0/Sp8 + ++++ ++++ ++++ + − ± ±
52
53
Neu5Acα2-3Galβ1-4(Fucα1-3)
GlcNAcβ-Sp0/Sp8
+ +++ ++++ +++ − − − −
10 NeuAcα2-3[6OSO3]Galβ1-4GlcNAcβ-Sp8 − − − − − − − −
49 Neu5Acα2-3Galβ1-4[6OSO3]GlcNAcβ-Sp8 − ++++ − +++ − − ± −
30 Neu5Acα2-3[6OSO3]Galβ1-4(Fucα1-3)GlcNAcβ-Sp8 − − − − − − − −
50 Neu5Acα2-3Galβ1-4(Fucα1-3)(6OSO3)GlcNAcβ-Sp8 − − − − − − ± −
31
32
Neu5Acα2-3(GalNAcβ1-4)
Galβ1-4GlcNAcβ-Sp0/Sp8
− − − − − − − −
54 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ-Sp8 + ++++ ++++ ++++ − − ± +
60 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 + ++++ ++++ ++++ +++ ++++ ++++ ++++
89 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 + ++++ ++++ ++++ ++ ++++ ++++ ++++
55 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-
3Galβ1-4GlcNAcβ-Sp8
+ ++++ ++++ +++ − − − ±
56 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-
4(Fucα1-3)GlcNAc-Sp0
− − − − − − − −
57 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-
4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0
+ ++++ ++++ ++++ ++ ++++ ++++ ++++
51 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4
(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0
+ ++++ ++++ ++++ + +++ ± ++++
47
48
Neu5Acα2-3Galβ1-3GlcNAcβ-Sp0/Sp8 + ++ ++++ ++ − − − ±
38 Neu5Acα2-3Galβ1-3(6OSO3)GlcNAc-Sp8 − − ++++ − − − − −
39 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp8 − − ++ − − − − −
88 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-
3GlcNAcβ-Sp0
± ± ++++ − − − − −
46 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-
4GlcNAcβ-Sp0
+ − ++++ − − + − ++
40 NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4
(Fucα1-3)GlcNAcβ-Sp0
− − − − − − − −
41 Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4)
GlcNAcβ-Sp8
+ ++++ ++++ ++++ − − − −
37 Neu5Acα2-3GalNAcβ1-4GlcNAcβ-Sp0 ± − +++ − − − − −
61
62
Neu5Acα2-3Galb1-4Glcβ-Sp8/Sp0 ± ++++ ++++ +++ − − − −
15
16
Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)
Galβ1-4Glcβ-Sp0/Sp9
− − − − − − − −
20
23
Galβ1-3GalNAcβ1-4(Neu5Acα2-3)
Galβ1-4Glcβ-Sp0
− − − − − − − −
33 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ-Sp0 − − − − − − − −
34 NeuAcα2-3(NeuAcα2-3Galβ1-3GalNAcβ1-4)
Galβ1-4Glcβ-Sp0
− − ++++ − − − − −
36 Neu5Acα2-3GalNAcα-Sp8 − − − − − − − −
24 Neu5Acα2-3Galβ1-3GalNAcα-Sp8 ± ++++ ++++ ++++ +++ ± ++++ +
42 Neu5Acα2-3Galβ1-3[6OSO3]GalNAcα-Sp8 ± ++++ ++++ ++++ +++ − ++++ −
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Table 1 (continued)
No. on
the graph
Glycans composition Virus 1 Virus 4 Virus 5 Virus 10 Virus 2 Virus 3 Virus 6 Virus 7
87 Galβ1-3-(Neu5Aα2-3Galβ1-4GlcNAcβ1-6)GalNAc-T − +++ ++++ ++ − − − −
45 NeuAcα2-3Galβ1-3GalNAcβ1-
3Galα1-4Galβ1-4Glcβ-Sp0 Gb5
− − − − − − − −
Glycoproteins 1 AGP (Alfa acid glycoprotein) ++++ ++++ ++++ ++++ ± − + −
2 AGP-A (Alfa acid glycoprotein-A) ++++ ++++ ++++ ++++ + − + −
3 AGP-β1 (Alfa acid glycoprotein-β1) ++++ ++++ ++++ +++ − − + −
4 Ceruloplasmin + ++ +++ + − − + −
5 Fibrinogen − − ± − − − − −
6 Transferrin ++ + ++ ++ − − + −
Other sialylated
glycans
7 α-Neu5Ac-Sp8 − − − − − − − −
8 α-Neu5Ac-Sp11 − − − − − − − −
9 β-Neu5Ac-Sp8 − − − − − − − −
11 9-O-AcNeu5NAcα-Sp8 − − − − − − − −
12 9-O-AcNeu5NAcα2-6Galb1-
4GlcNAcβ-Sp8
− − − − − − − −
21 KDNα2-3Galβ1-3GlcNAcβ-Sp0 − − − − − − − −
22 KDNα2-3Galβ1-4GlcNAcβ-Sp0 − − − − − − − −
25 Neu5Acα2-8NeuAcα2-8NeuAcα2-
8NeuAcα2-3(GalNAcβ1-4)Galβ1-
4Glcβ-Sp0
− − − − − − − −
26 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-
3(GalNAcβ1-4)Galβ1-4Glcβ-Sp0
− − − − − − − −
27 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-
3Galβ1-1–4Glcβ-Sp0
− − − − − − − −
28 Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-
4)Galβ1-4Glcβ-Sp0
− − − − − − − −
29 Neu5Acα2-8Neu5Acα2-8Neu5Acα-Sp8 − − − − − − − −
74 Neu5Acα2-8Neu5Acα-Sp8 − − − − − − − −
75 Neu5Acα2-8Neu5Acα2-3Galβ1-
4Glcβ-Sp0
− − − − − − − −
76 Neu5Acβ2-6GalNAcα-Sp8 − − − − − − − −
77 Neu5Acβ2-6Galβ1-4GlcNAcβ-Sp8 − − − − − − − −
78 Neu5Acβ2-6(Galβ1-3)GalNAcα-Sp8 − − − − − − − −
79 Neu5Gcα2-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 − − − − − − − −
80 Neu5Gcα2-3Galβ1-3GlcNAcβ-Sp0 − − − − − − − −
81 Neu5Gcα2-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 − − − − − − − −
82 Neu5Gcα2-3Galβ1-4GlcNAcβ-Sp0 − − − − − − − −
83 Neu5Gcα2-3Galβ1-4Glcβ-Sp0 − − − − − − − −
84 Neu5Gcα2-6GalNAcα-Sp0 − − − − − − − −
85 Neu5Gcα2-6Galβ1-4GlcNAcβ-Sp0 − − − − − − − −
86 Neu5Gcα-Sp8 − − − − − − − −
Spacers:
Sp0 CH2CH2NH2
Sp8 CH2CH2CH2NH2
Sp9 CH2CH2CH2CH2CH2NH2
Sp10 NHCOCH2NH
Sp11 OCH2C6H4-p-NHCOCH2NH
T Threonine
a The relative afﬁnity of the viral HA to the corresponding glycan is represented in the table in an arbitrary scale from “high” (++++) to “low” (+); (−) represents that no
binding was detected.
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neuraminic acid (Neu5Gc), KDN, and 9-O-acetylneuraminic acid (9-
O-AcNeu5NAc), were not recognized by the viruses. The sialic acid
as a monosaccharide was not bound by the viruses. The
disaccharide consisting of terminal sialic acid attached to galactose
via α2-3 or α2-6 glycosidic linkage (Neu5Acα2-3/6Gal−) was
found to be the minimal indispensable structure that could result in
detectable virus binding. Linkage through β conﬁguration
(Neu5Acβ2-6Gal−) or to another sialic acid (Neu5Acα2-
8Neu5Acα2−) precluded virus binding. Modiﬁcation of the sialy-
lated subterminal galactose by attachment of an additional sugar or
other moiety (e.g., sulfate) also prevented virus binding. Although
the Neu5Acα2-3/6Gal- is an indispensable structure for virus
binding, in many cases a longer oligosaccharide chain was
necessary for detectable virus binding, although the conﬁguration
of the inner core of the glycan can play a crucial role in receptor–
virus interaction. As an example, the sialylated Globo-series glycan
(Gb5, also known as SSEA3a) turned out to be impermissible for
binding by any of the tested viruses.Virus variant 1, which represents parental virus with low-growth
capabilities in eggs, bound preferentially the trisaccharide motifs
consisting of N-acetyllactosamine (Type-II motif) terminally sialy-
lated via α2-6 glycosidic linkage. Another effectively bound structure
was a trisaccharide formed byα2-6-sialylated LacdiNAc. The array did
not contain other known motifs (e.g., Type-I or Type-III) terminally
sialylated via α2-6 glycosidic linkage. The α2-6 sialylated lactose as
well as shorter glycans, such as sialylated galactose or N-acetylga-
lactosamine, was also bound by the virus, although with substantially
lower afﬁnity. Only very weak binding was observed with linear
glycans terminally sialylated via α2-3 glycosidic linkage. Such a clear
preference for structures with α2-6 glycosidic linkage may not be
surprising, taking into account the human origin of inﬂuenza B viruses
and consistent with the previous reports (Couceiro et al., 1993;
Gambaryan and Matrosovich, 1992, Gambaryan et al., 1995, 1997,
1999; Govorkova et al., 1995; Suzuki, 1994, 2005; Suzuki et al., 1987,
1989, 1992 ; Williams and Robertson, 1993; Xu et al., 1994, 1996).
Although all three amino acid substitutions described in this report
were found in association with improved virus replication in eggs,
224 V.Y. Lugovtsev et al. / Virology 394 (2009) 218–226each of them had its own unique glycan-binding features. Interest-
ingly, two substitutions, R162M and D196Y, had almost identical
effects on viral receptor-binding proﬁles, expanding the spectrum of
the glycans that could be bound by the virus. Viruses possessing either
or both of the mutation were able to bind efﬁciently not only theα2-6
sialylated glycans that were bound by the parental virus (variant 1)
but also a variety of the glycans with α2-3 glycosidic linkage. The
spectrum of bound α2-3 terminally sialylated glycans includes all
linear motifs represented on the array: Type-I, Type-II, and Type-III
motifs, with the exception of LacdiNAc, which was bound, although
very weakly, only by the virus containing substitution R162M. The
crystal structure of the HA of inﬂuenza B virus B/Hong Kong/8/73
(Wang et al., 2007) revealed that amino acid at position 196 is a part
of the loop (amino acids 195–204 of HA) that forms one of the edges
of the receptor-binding domain. It was shown that the aspartic acid at
position 196 as well as the adjacent amino acids of that loop play an
important role in providing additional bonds to the inner part of the
receptor (ﬁfth saccharide), especially when it terminally sialylated via
α2-3 linkage. At the same time, our data showed that this amino acid
change improved binding even with short glycan structures consist-
ing of only three saccharides. Interestingly, although the amino acid at
position 162 is not a part of the receptor-binding site and has no direct
contact with the receptor, the R162M change had a similar effect to
that produced by the D196Y substitution. The only difference was that
R162M contributed to slightly better binding of modiﬁed Type-Imotif,
especially its sulfated and fucosylated forms, as well as LacdiNAc with
α2-3 linkage, whereas D196Y change improved the binding of the
sulfated derivatives of the Type-II motif. The binding proﬁle of the
virus variant 10 containing both amino acid changes is most similar to
that of the virus variant 4 with D196Y, demonstrating the dominant
effect of the latter.
Amino acid 141 had a more dramatic role in receptor binding. It
not only forms one of the edges of the binding domain but also
contacts directly the sialic acid portion of the receptor creating one or
two hydrogen bonds (Wang et al., 2007). The amino acids at positions
139, 140, and 141 are conserved among the virus isolates and form the
anchoring site for the sialic acid moiety of the receptor. The
overwhelming majority of inﬂuenza B isolates have a glycine at
position 141. Therefore, it is not surprising that replacement of glycine
by glutamic acid had a dramatic effect on the receptor-binding
properties. Possibly, the bulkiness of the glutamic acid substantially
changes the shape of the binding pocket, making it shallow and
narrowing the entry point to the sialic acid, whereas the negative
charge could also play a role in repelling the negatively charged sialic
acid (Gambaryan et al., 1998, 1999; Kaverin et al., 2000). Virus
variants with substitution G141E completely lost the ability to bind
any glycan structure terminally sialylated via α2-6 linkage, and only
several glycans with α2-3 linkage were bound. The best binding was
observed with linear pentasaccharides especially with α2-3 sialylated
Type-II motif, but even in those cases the afﬁnity was signiﬁcantly
lower compared to that of the viruses without G141E change.
Noteworthy, the G141E substitution was the most beneﬁcial for
virus replication in eggs (Lugovtsev et al., 2007), demonstrating that
the afﬁnity of the viral HA to only a few types of glycans with α2-3
linked sialic acid is sufﬁcient for efﬁcient virus replication in that host.
Combination of the substitution G141Ewith either or both R162M and
D196Y resulted in binding proﬁles similar to that of the virus with
G141E alone, demonstrating that the effect of the G141E substitution
was the most dominant of those tested here. The only noticeable trace
of the effect of two substitutions R162M and D196Y on the
background of G141E was the ability to bind α2-3 sialylated Type-
III motif (Core 1) in addition to the α2-3 sialylated Type-II motif.
Interestingly, although all mutant viruses analyzed in this study have
some unique features in their binding proﬁle, all of them share a high
afﬁnity to the long oligosaccharides with non-reducing end repre-
sented byα2-3-sialylated Type-II motif. This observation is consistentwith previous reports showing a predominance of long N-linked
glycan structures (bi-antennary with high-mannose core) with α2-3
sialylated Type-II motif on the cells of chorioallantoic membrane of
chicken eggs (Ito et al., 1997; Sriwilaijaroen et al., 2008). However, the
signiﬁcance of virus binding to O-linked glycans (including ganglio-
sides and glycolipids) and their representation in embryonated
chicken eggs requires further studies.
Taken together, it is possible to propose the followingmodel of the
B/Victoria/504/2000 adaptation to high-growth replication in eggs.
At the beginning of the adaptation, mutants in the original virus
population, such as those containing R162M and D196Y, were
selected for their expanded capability to bind a wide spectrum of
bothα2-3 andα2-6 sialylated glycans rather than justα2-6 sialylated
glycans. From such virus variants able to infect a variety of permissible
cells of the chicken embryo, new variants of the virus population
would be selected with the best ﬁtness and highest replication rate.
Eventually, high-growth virus variants would emerge that have lost
the ability to bind all the “unnecessary” and trapping types of glycans
but retained the ability to bind a few most appropriate receptors. The
tuning of the binding speciﬁcity of the viral HA would be associated
not only with adaptation to the new target cells but also with a
selection of receptors that can be effectively cleaved by the viral
neuraminidase at the last stage of viral replication cycle, promoting
efﬁcient release and dissemination of the progeny virus particles.
However, the substrate speciﬁcity of the NA and the functional
balance of the HA and NA in case of this particular virus strain has yet
to be determined.
Materials and methods
Viruses
Viruses used in this study were created by reverse genetics and
described elsewhere (Lugovtsev et al., 2007). Virus variant 1 contains
all genome segments identical by consensus nucleotide sequences to
that of the natural virus strain B/Victoria/504/2000 after 12 passages
in eggs (Lugovtsev et al., 2005). All other virus variants differ from the
variant 1 only by speciﬁed amino acid substitutions in their HA. For
glycan array analysis, viruses were propagated in eggs, concentrated
and puriﬁed through a discontinuous sucrose density gradient with
banding on the 60% sucrose cushion. Puriﬁed virus particles were
labeled with the ﬂuorescent dye Alexa-488 (Alexa Fluor® 488
carboxylic acid, succinimidyl ester mixed isomers; Molecular Probes)
as described earlier (Kumari et al., 2007) with minor modiﬁcations.
Brieﬂy, puriﬁed virus preparations resuspended to a concentration
5000–10,000 HAU/ml in a CaMgS (0.15 M NaCl, 0.25 mM CaCl2,
0.8 mM MgCl2, pH 7.2) were mixed with a freshly prepared working
solution of Alexa-488 (10 μg/μl in dimethylformamide) in a ratio of
microgram of dye per 1 HAU ranging between 0.005 and 0.0008 μg/
HAU (the ratio was determined experimentally during protocol
optimization and provides most reproducible results with strong
ﬂuorescent signal with no inhibition of binding properties). After
stirring for 1 h at room temperature in the dark, the sample (150 μl)
was dialyzed (Slide-A-Lyzer Mini Dialysis Units 7000 MWCO; Pierce)
against 1.0 L of CaMgS (pH 7.2) at 4 °C overnight (with a total of 3×1.0
L changes of the solution). The HA titer of labeled viruses was checked
again prior to glycan array analysis.
Glycan microarray analysis
Analyses of the receptor speciﬁcity of the viruses were performed
by the protein–carbohydrate interaction core (Core H) of the
Consortium of Functional Glycomics (www.functionalglycomics.org)
using version 2.1 of the glycan array printed as previously described
(Blixt et al., 2004; Paulson et al., 2006; Stevens et al., 2006b). The array
version v2.1 contains 285 sialylated and non-sialylated glycan
225V.Y. Lugovtsev et al. / Virology 394 (2009) 218–226structures. Since no virus binding was observed with non-sialylated
glycans (data not shown) for simplicity and legibility, the graphs and
tables were modiﬁed to include data only for the 89 structures
containing sialic acid moieties. The concentration of the labeled
viruses was in the range of 5000–10,000 hemagglutinating units
(HAU) per 1.0 ml, as determined by a standard procedure in
hemagglutination test with 0.5% chicken red blood cells (Palmer et
al., 1975). To obtain consistent and reproducible data and to minimize
the effect of inherent variability associated with the quality of virus
preparation, ﬂuorescent dye labeling, and glycan array chip manu-
facture, all viruses were analyzed several times in independent
experiments. The data chart for each virus shown in Fig. 1 is a data
from a single representative experiment. The array composed of
glycans printed in replicate (n=6), where the relative ﬂuorescence
unit (RFU) values are an average of four values after removal of the
highest and lowest of the six replicates. Table 1 contains cumulative
data from several independent experiments.
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